絞り込み

17416

広告

A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis.

著者 Iwakiri K , Sakurai Y , Shiino M , Okamoto H , Kudou K , Nishimura A , Hiramatsu N , Umegaki E , Ashida K
Therap Adv Gastroenterol.2017 Jun ; 10(6):439-451.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (340view , 0users)

Full Text Sources

Medical

Standard treatment for patients with erosive esophagitis (EE) is proton-pump inhibitors (PPIs), but some patients are resistant to PPIs. We aimed to evaluate the acid-inhibitory effects and efficacy of a novel potassium-competitive acid blocker (vonoprazan) in patients with PPI-resistant EE.
PMID: 28567114 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード